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Abstract
Background: Venous thromboembolism (VTE) is a major health and financial burden. VTE impacts health
outcomes in surgical and non-surgical patients. VTE prophylaxis is underutilized, particularly amongst high risk
medical patients. We conducted a multicentre clinical audit to determine the extent to which appropriate VTE
prophylaxis in acutely ill hospitalized medical patients could be improved via implementation of a multifaceted
nurse facilitated educational program.
Methods: This multicentre clinical audit of 15 Australian hospitals was conducted in 2007-208. The program
incorporated a baseline audit to determine the proportion of patients receiving appropriate VTE prophylaxis
according to best practice recommendations issued by the Australian and New Zealand Working Party on the
Management and Prevention of Venous Thromboembolism (ANZ-WP recommendations), followed by a 4-month
education intervention program and a post intervention audit. The primary endpoint was to compare the
proportion of patients being appropriately managed based on their risk profile between the two audits.
Results: A total of 8774 patients (audit 1; 4399 and audit 2; 4375) were included in the study, most (82.2% audit 1;
and 81.0% audit 2) were high risk based on ANZ-WP recommendations. At baseline 37.9% of high risk patients
were receiving appropriate thromboprophylaxis. This increased to 54.1% in the post intervention audit (absolute
improvement 16%; 95% confidence interval [CI] 11.7%, 20.5%). As a result of the nurse educator program, the
likelihood of high risk patients being treated according to ANZ-WP recommendations increased significantly (OR
1.96; 1.62, 2.37).
Conclusion: Utilization of VTE prophylaxis amongst hospitalized medical patients can be significantly improved by
implementation of a multifaceted educational program coordinated by a dedicated nurse practitioner.
Introduction
Venous thromboembolism (VTE), which comprises deep
vein thrombosis (DVT) and pulmonary embolism (PE)
represents a major public health problem. VTE is primar-
ily a problem in hospitalized or recently hospitalized
patients. The incidence of VTE has been shown to be
more than 100 times greater among hospitalized patients
than those in the community [1]. In Australia, VTE is
estimated to complicate 2-3 per 1000 hospital admis-
sions, but varies widely by principle diagnosis [2]. More-
over, postmortem studies indicate that approximately
10% of all hospital deaths are attributed to PE, [3-5] mak-
ing it the most common preventable cause of hospital
death [6].
In recent years, the prevention of VTE has been iden-
tified nationally and internationally as a priority area for
improving patient safety. To support these efforts, a
number of evidence-based guidelines have been made
available which outline the appropriate use of prophy-
laxis to prevent VTE in a variety of patient populations
[7-13]. Patients should be treated according to their
individual risk and associated clinical conditions
[7,11,14]. The Australian and New Zealand Working
Party on the Management and Prevention of Venous
Thromboembolism (ANZ-WP), which first convened in
1997, has sought to provide a practical pocket-sized
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prevention. The most recently published version of
these recommendations [15] is based on guidelines from
the International Union of Angiology [8] and the Ameri-
can College of Chest Physicians (ACCP) [7] and state
that every hospitalized adult patient should be assessed
for their risk of VTE.
Despite the commonly held perception that VTE is a
complication of major surgery, postmortem studies have
shown that approximately 70% of fatal PEs occur in
non-surgical patients [3-5]. Further, it is accepted in the
literature that 50-70% of symptomatic thromboembolic
events occur in non-surgical patients [7,14]. Neverthe-
less, the evidence base for clinical decision making
regarding thromboprophylaxis in medical patients
remains limited. Data from two meta-analyses demon-
strate relative risk reductions of between 38% and 57%
with the use of pharmacological prophylaxis depending
on the endpoint being assessed [16,17]. These data have
recently been corroborated by the National Health and
Medical Research Council of Australia, who present
relative risk reductions of between 39% and 60% with
the use of pharmacological prophylaxis in general medi-
cal patients admitted to hospital [12].
Available published data from multinational observa-
tional studies demonstrate the underuse or suboptimal
use of VTE prophylaxis to be a global problem. In the
IMPROVE (International Medical Prevention Registry
on Venous Thromboembolism) study, which assessed
routine clinical practices in the provision of VTE pro-
phylaxis in acutely ill hospitalized medical patients from
52 hospitals in 12 countries, only 60% of patients who
met the criteria for prophylaxis actually received it [18].
The global ENDORSE (Epidemiologic International Day
for the Evaluation of Patients at Risk for Venous
Thromboembolism in the Acute Hospital Care Setting)
study evaluated over 68,000 patients in 365 hospitals
across 32 countries, again showing that amongst the
surgical patients at risk only 58.5% received ACCP-
recommended VTE prophylaxis whilst this was even
lower (39.5%) amongst at-risk medical patients [19].
Further analysis of the ENDORSE study data has shown
that whilst the use of prophylaxis differs between coun-
tries, in general its use appears to be associated with dis-
ease severity rather than medical diagnosis [20].
This global picture also extends to Australia. A study
of 250 surgical patients at the Royal Hobart Hospital,
Tasmania, found that only 59.2% of patients had
received appropriate prophylaxis according to the hospi-
tal’s approved guidelines [21]. Amongst patients at high
risk of VTE, only 25.7% were prescribed the recom-
mended preventive measures. Similarly, in 2002 it
was reported that the majority of inpatients in The
Canberra Hospital (TCH) were not receiving appropriate
prophylaxis according to international guidelines [22,23].
More recently, in the ENDORSE study, 80% of surgical
patients were at risk for VTE yet only 72% received
ACCP-recommended treatment. Consistent with global
trends medical patients again fared worse with only 42%
of those at risk receiving ACCP-recommended treat-
ment [19].
There is a clear need for improved implementation of
existing guidelines. Various strategies have been
employed and their effectiveness systematically reviewed
[24,25]. Passive dissemination of guidelines was found to
be the least effective method whilst the most effective
strategies combined a system of active education of
health providers, the use of reminders to assess for VTE
risk and iterative audit and feedback to enable a contin-
uous cycle of quality improvement. When such a pro-
cess was employed at the Royal Hobart Hospital,
Tasmania, a significant increase in adherence to guide-
lines resulted, the biggest improvement being amongst
patients at high-risk (from 25.7% pre-intervention to
76.5% post-intervention) [21]. Similarly, data collected in
TCH over the period 2001-2005 as part of a quality
improvement program highlighted that, at baseline,
there was a clear absence of policies to assess and
respond to patient risk. This improved over the duration
of the study; there was a statistically significant increase
in the use of risk assessment in the ward setting (from
7.7% to 100%) and in the extent of coverage of patients
with anticoagulant prophylaxis (from 48% to 74%) [23].
In this paper we report the results of a multicentre
clinical audit study examining the effect of a dedicated
VTE nurse educator on the use of prophylactic mea-
sures in acutely ill medical patients at 15 hospitals
across Australia. The specific aims of the audit were to
determine the extent to which appropriate VTE prophy-
laxis is being utilized at baseline and to examine the
impact of a multifaceted program on the rate of appro-
priate VTE prophylaxis.
Methods
The VTE Task Force Audit was a multicentre clinical
program performed in 15 hospitals throughout Australia,
and conduced over the period June 2007 to August 2008.
The use of VTE prophylaxis in acutely ill medical
patients was assessed prior to and following an interven-
tional program implemented by a dedicated VTE nurse
educator. The audit was conducted in accordance with
the Declaration of Helsinki as amended in 2004 [26] and
written approval was obtained from the relevant human
research ethics committee at each study site. Each study
site performed a baseline audit of the VTE risk and admi-
nistered prophylaxis on 200-300 consecutively presenting
adult (≥18 years of age) patients admitted to hospital for
an acute medical illness with an in-hospital stay of 3 days
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multi-faceted program of system change comprising
active educational sessions, paper and verbal reminders
and feedback of the initial audit results. A second audit
of another 200-300 consecutive medical patients was per-
formed four months after the institution of the program.
The proportion of patients receiving appropriate VTE
prophylaxis was compared at baseline and following the
program to assess its efficacy. Full details of the study
methodology (patient selection, data collection, primary
endpoints, educational program, analyses and statistical
analysis) have been published previously in a design
paper [27].
Recommendations for the prevention of VTE issued
by the ANZ-WP [15] (ANZ-WP recommendations)
were used for assessment of risk and suitability for
anticoagulant or mechanical prophylaxis. For the pur-
poses of our audit, medical patients were classified as
being at either “high” or “low” risk, as defined at step 1
in the ANZ-WP recommendations (Figure 1) [15]. All
analyses are based on the intent to treat population,
which comprised all patients for whom a case record
form was submitted.
Results
A total of 8774 patients (audit 1; 4399 and audit 2;
4375) from 20 clinical units within 15 hospitals were
included in the study. Each hospital met the target
recruitment criteria of 200-300 patients for each audit
(Table 1). The demographic profiles of patients included
in the baseline and post intervention audits were similar
(Table 2).
The majority of patients (audit 1; 3618 [82.2%] and
audit 2; 3544 [81.0%]) were classified as high VTE risk
based on the ANZ-WP recommendations. Amongst
those patients classified as being at “high-risk”, the most
frequent of the risk factors were age >60 years (87.8%
and 88.9% for audits 1 and 2, respectively), acute or
chronic lung disease (21.1% and 19.5% for audits 1 and
2, respectively) followed by active cancer (Figure 2). The
presence of multiple risk factors amongst these patients
was common and similar in each audit; 63% and 66% in
audits 1 and 2, respectively had one risk factor, 35% and
Figure 1 VTE risk classification in medical patients. Reproduced with permission from: The Australia and New Zealand Working Party on the
Management and Prevention of Venous Thromboembolism. Prevention of venous thromboembolism: best practice guidelines for Australia and
New Zealand. 4th Edition. 2007. Sydney, Health Education and Management Innovations.
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respectively had three risk factors.
Prophylaxis protocols were in place in 44.2% (69/156)
of the hospital units involved in audit 1 and 49.3% (67/
136) of those involved in audit 2. Amongst hospital
units that did not have a prophylaxis protocol in place
at audit 1, 5.3% had introduced a protocol by the com-
mencement of audit 2 (95% CI 2.1% to 10.5%, P <
0.0001). One third (5/15) of hospitals had prophylaxis
protocols in all of their units for both audits. Protocols
were in place for both audits in all of the gastroenterol-
ogy, renal medicine, rheumatology, geriatric and stroke
units of all participating hospitals.
Contra-indications to anticoagulant prophylaxis were
common (21.4% and 26% in audits 1 and 2, respec-
tively). The most common contraindication in both
audits was current therapeutic LMWH/UFH/warfarin;
which accounted for almost half of all contraindications
(audit 1: 10.5% and audit 2: 11.7%). Contra-indications
to anticoagulant prophylaxis were more common in
patients classified as being at high VTE risk than in
those at lower risk.
The primary endpoint of this study was to determine
whether or not a patient was being appropriately mana-
ged based on their VTE risk profile. The proportion of
patients being treated according to the ANZ-WP recom-
mendations increased significantly between audits
(Figure 3); the absolute improvement versus baseline
was 12.4% (95%CI 8.8-16.1, p < 0.001) in all patients
and 16.1% (95%CI 11.7-20.5, p < 0.001) in patients clas-
sified as being at high risk. The improvement in appro-
priate prophylaxis in high risk patients occurred due to
an increase in both the number of patients prescribed
anticoagulants and also in the number receiving com-
pression stockings [audit 1 7.6% versus audit 2 18.1%;
absolute change 10.5%; 95%CI 5.8-15.2] in whom a con-
tra-indication to anticoagulants existed. In audit 1, a
higher percentage of patients were being treated with
enoxaparin (16%, 95%CI 12.8-19.3) than unfractionated
Table 1 Contribution of patients from individual study
sites
Hospital Baseline
(Audit 1)
Post intervention
(Audit 2)
Ballarat Hospital 236 (5.4) 300 (6.9)
Concord Repatriation General
Hospital
300 (6.8) 299 (6.8)
Dandenong Hospital 300 (6.8) 300 (6.9)
Fremantle Hospital 300 (6.8) 267 (6.1)
Greenslopes Hospital 298 (6.8) 297 (6.8)
Liverpool Hospital 297 (6.8) 300 (6.9)
Mater Adult Hospital 299 (6.8) 239 (5.5)
Monash Medical Centre 300 (6.8) 300 (6.9)
Nambour Hospital 301 (6.8) 297 (6.8)
Queen Elizabeth Hospital 270 (6.1) 278 (6.4)
Royal Brisbane Hospital 298 (6.8) 298 (6.8)
Royal North Shore Hospital 300 (6.8) 300 (6.9)
St George Hospital 300 (6.8) 300 (6.9)
Western Hospital 300 (6.8) 300 (6.9)
Westmead Hospital 300 (6.8) 300 (6.9)
TOTAL 4399 (100) 4375 (100)
All values presented as number (%).
Table 2 Patient demographics
Baseline
(Audit 1)
Post intervention
(Audit 2)
Gender
Male, n (%) 2243 (51.0) 2211 (50.5)
Female, n (%) 2156 (49.0) 2164 (49.5)
Mean age in years (SD) 69.0 (18.26) 69.7 (17.68)
Mean weight in kg (SD) 74.6 (21.9) 74.3 (23.3)
High risk*, n (%) 3618 (82.2) 3544 (81.0)
n = number; SD = standard deviation *High risk = Age >60 years or admission
due to acute respiratory disease, heart failure, malignancy, ischaemic stroke,
rheumatological or inflammatory or existence of previous VTE[15].
Figure 2 Risk factors for VTE based on ANZ-WP best practice
recommendations [15].
Figure 3 Proportion of patients receiving appropriate VTE
prophylaxis in the baseline and post intervention audits.
Gibbs et al. Thrombosis Journal 2011, 9:7
http://www.thrombosisjournal.com/content/9/1/7
Page 4 of 6heparin (10.9%, 95%CI 8.0-13.8), whereas in audit 2,
enoxaparin (17.3%, 95%CI 12.2-22.4) and unfractionated
heparin (17.3%, 95%CI 11.8-22.7) were used equally.
The likelihood of any patient being treated according to
ANZ-WP recommendations increased significantly as a
result of the nurse educator program; odds ratio (OR,
95% CI) 1.68 (1.45, 1.94). Amongst patients classified as
high risk, the odds of being treated according to the
recommendations as a result of the nurse education pro-
gram was nearly 2 (OR 1.96; 1.62, 2.37) and was higher
when a unit protocol was present (OR 2.46; 1.85, 3.28).
Discussion
Our study evaluated the use of thromboprophylaxis
amongst almost 9000 acutely ill medical patients
admitted to 15 hospitals across Australia. At baseline
fewer than 2 out of 5 patients classified as being at high
risk were receiving appropriate VTE prophylaxis. Feed-
back of the baseline results to the relevant medical, nur-
sing and allied health staff and education implemented
by a dedicated VTE nurse educator at each hospital
resulted in significant improvements in patient care. As
a result of this multifaceted education program, the like-
lihood of a high risk patient being managed appropri-
ately increased by 42%.
Clinical audits, whilst valuable educational tools, are
not without their limitations. Our study utilised a simple
before and after design, which may be subject to metho-
dological limitations [28]. Confounding issues, such as
the relative experience of the medical staff at the time
of each audit were likely to be minimal given that the
first cycle of data collection occurred mid-year when
trainees would have had at least 6 months experience.
The proportion of patients audited in each cycle did not
differ significantly either by hospital unit or reason for
admission. Having only one post-implementation data
point makes it difficult to determine whether the
improvements we observed would be maintained or
improved upon over the longer term. Ongoing support
a p p e a r st ob eaak e yc o m p o n e n to fs u c c e s si nt h i s
respect. Gallagher et al reported an initial increase in
VTE risk assessment rates, followed by a fall and then a
further increase (to 100%) over a 4-year period of
ongoing data collection, feedback and education [23].
VTE can lead to serious illness or death, long term
morbidity, prolonged length of stay, and increased hospi-
tal costs. The goals of VTE prophylaxis - risk assessment
followed by prescription of appropriate prophylaxis - are
well established. It is further established that multiple
active strategies which incorporate reminders for clini-
cians to assess patients for VTE risk and assist in the
selection of appropriate prophylactic measures are more
likely to result in improvements [24,25]. However, to
effect change in VTE prophylaxis practice requires a
combination clinical leadership, improved clinician
knowledge of risk assessment and appropriate prescrib-
ing, and a supportive system which embeds VTE prophy-
laxis into routine care processes.
In the US, it has been mandated that hospitals use
formalised tools for VTE risk assessment and provide
appropriate prevention measures [29,30]. Guidelines,
protocols and VTE prevention programs have been
implemented in Australia, but to date mandatory order
sets or risk assessment protocols have not been estab-
lished and clinician preference appears to be a key dri-
ver in the prescription of prophylaxis.
It has been suggested that through leadership and edu-
cation nurses are ideally placed to play a central role in
the implementation of changes to ensure that patients
are assessed and the most appropriate thromboprophy-
laxis selected, prescribed and delivered [31]. Our study is
the first multicentre clinical audit conducted to deter-
mine the extent to which VTE risk is assessed and mana-
ged in acutely ill medical patients in Australia. We have
demonstrated that, via the employment of a full-time
prophylaxis nurse, a combination of audit and feedback,
education and visual reminders significantly increased
the rate of appropriate VTE prophylaxis in acutely ill
hospitalized medical patients. The results, whilst not pro-
viding all the answers to this important clinical issue,
provide encouragement and support to those seeking to
implement change. Cost-efficacy data will be required to
determine the net long-term benefits of employing a full-
time prophylaxis nurse and would also likely be required
before mandatory systems are established.
Conclusion
Our results confirm prior findings that, despite the
availability of management guidelines and prophylaxis
protocols, VTE prophylaxis is underutilised in acutely ill
hospitalised medical patients in Australia. Implementa-
tion of a multifaceted educational program coordinated
by a dedicated nurse practitioner resulted in significant
improvements in appropriate prophylaxis. Amongst
acutely ill medical patients at high risk of VTE, the like-
lihood of being treated according to guideline increased
significantly as a result of this nurse education program.
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